PMID- 19951570
OWN - NLM
STAT- MEDLINE
DCOM- 20100304
LR  - 20101118
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 122
IP  - 21
DP  - 2009 Nov 5
TI  - Effects of five-year intensive multifactorial intervention on the serum amyloid A 
      and macroangiopathy in patients with short-duration type 2 diabetes mellitus.
PG  - 2560-6
AB  - BACKGROUND: A five-year follow-up study of intensive multifactorial intervention 
      was undertaken to assess the changes of circulating serum amyloid A (SAA) levels 
      and the incidence of atherosclerosis (AS) in patients with short-duration type 2 
      diabetes mellitus (T2DM) without macroangiopathy, and whether intensive 
      multifactorial intervention could prevent or at least postpone the occurrence of 
      macroangiopathy. METHODS: Among 150 patients with short-duration T2DM, 75 were 
      assigned to receive conventional outpatient treatment (conventional group) and 
      the others underwent intensive multifactorial integrated therapy targeting 
      hyperglycemia, hypertension, dyslipidemia and received aspirin simultaneously 
      (intensive group). RESULTS: Plasma SAA levels were higher in diabetic patients 
      than those in healthy control subjects, and decreased obviously after intensive 
      multifactorial intervention. The levels of SAA were positively correlated with 
      body mass index (BMI), waist hip ratio (WHR), triglyceride (TG), high sensitive 
      C-reactive protein (hs-CRP) and common carotid intima-media thickness (CC-IMT). 
      The standard-reaching rates of glycemia, blood pressure and lipidemia were 
      significantly higher in intensive group than those of conventional group. The 
      incidence of macroangiopathy decreased by 58.96% in intensive group compared with 
      conventional group. CONCLUSIONS: Intensive multifactorial intervention may 
      significantly reduce the SAA levels and prevent the occurrence of AS in 
      short-duration patients with T2DM. SAA might be one of the risk factors of T2DM 
      combined with AS.
FAU - Du, Jian-ling
AU  - Du JL
AD  - Department of Endocrinology, First Affiliated Hospital of Dalian Medical 
      University, Dalian, Liaoning 116011, China.
FAU - Liu, Jian-feng
AU  - Liu JF
FAU - Men, Li-li
AU  - Men LL
FAU - Yao, Jun-jie
AU  - Yao JJ
FAU - Sun, Li-peng
AU  - Sun LP
FAU - Sun, Guo-hua
AU  - Sun GH
FAU - Song, Gui-rong
AU  - Song GR
FAU - Yang, Yu
AU  - Yang Y
FAU - Bai, Ran
AU  - Bai R
FAU - Xing, Qian
AU  - Xing Q
FAU - Li, Chang-chen
AU  - Li CC
FAU - Sun, Chang-kai
AU  - Sun CK
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Serum Amyloid A Protein)
RN  - 0 (Triglycerides)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/pharmacology/therapeutic use
MH  - Blood Glucose/metabolism
MH  - C-Reactive Protein/metabolism
MH  - Diabetes Mellitus, Type 2/*complications/drug therapy/*metabolism
MH  - Diabetic Angiopathies/*etiology
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Hypolipidemic Agents/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Serum Amyloid A Protein/*metabolism
MH  - Triglycerides/blood
MH  - Tunica Media/drug effects
EDAT- 2009/12/03 06:00
MHDA- 2010/03/05 06:00
CRDT- 2009/12/03 06:00
PHST- 2009/12/03 06:00 [entrez]
PHST- 2009/12/03 06:00 [pubmed]
PHST- 2010/03/05 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2009 Nov 5;122(21):2560-6.